Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Eli Lilly and Company has received FDA approval for CYRAMZAâ„¢ (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after...

The specialty pharmaceutical company Valeant Pharmaceuticals International Inc. has made an approximate $45.7 billion unsolicited bid for specialty pharmaceutical company Allergan, Inc.. Allergan has acknowledged the bid, but says it plans to take...

Glenmark Generics has issued a Class II voluntary recall of 2904 bottles of rantidine Tablets USP, 150 mg, 500-count bottles, prescription only, due to a pharmacist complaint of a "foreign material,"  identified as a metoprolol tartrate...

Mylan Inc. reports that its US-based subsidiary Mylan Pharmaceuticals Inc. has launched Xulane™ (norelgestromin/ethinyl estradiol transdermal system 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s Ortho Evra®...

Teva Pharmaceutical Industries Ltd. reports that its subsidiary, Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of the anti-arthritis drugCelebrex® (celecoxib) 50-, 100-, 200- and...

Mylan Inc. has launched eszopiclone tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta®. Mylan received final FDA approval for its abbreviated new drug application (ANDA) for this product, which is...

Mylan Inc. and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC (now part of Actavis), settling the parties' litigation in connection with Mylan's filing of an abbreviated new drug...